Drugs / Invaplex 50
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00082069 | Apr 2004 → Nov 2006 | diarrheal disease | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00485134 | May 2007 → Jul 2009 | shigellosis | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Invaplex 50 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00082069 ↗ |
| Known as | Shigella flexneri Invaplex 50 | “The Shigella flexneri Invaplex 50 is a macromolecular complex containing IpaB, IpaC, and LPS, formulated from an aqueous extract of virulent Shigella delivered via nasal administration.” PMID 20619378 ↗ Jul 2010 |
| Modality | Vaccine | “The Invaplex 50 nasal vaccine was safe with encouraging mucosal immune responses.” PMID 20619378 ↗ Jul 2010 |
| Route | Intranasal | “The Shigella flexneri Invaplex 50 is a macromolecular complex containing IpaB, IpaC, and LPS, formulated from an aqueous extract of virulent Shigella delivered via nasal administration.” PMID 20619378 ↗ Jul 2010 |